Supplemental Figures:

Blocking studies in non-human primates (n=2) were performed as previously described.¹ In the current study, the images were reformatted into standard cardiac planes to facilitate optimal placement of the regions-of-interest used to calculate the standardized uptake values (SUVs).



Figure S1: Blocking of [¹¹C]Martinostat uptake in the heart by pre-injection of cold compound. (A, B) Short axis images of the heart acquired (A) without blocking and (B) with blocking through pre-injection of non-radioactive Martinostat. The signal from the probe in the liver is similar. However, pre-injection of cold compound markedly attenuates the intensity of [¹¹C]Martinostat in the myocardium. (C) The percent-difference in the SUVs, normalized to the unblocked values, increases with time and reaches a peak of 75%.



Figure S2: Specificity of [¹¹**C]Martinostat for myocardial HDAC demonstrated by blocking with a competitive HDAC inhibitor.** Baseline images of the heart in (A) the 4chamber view and (B) the short axis view are shown. (C, D) Corresponding images acquired after the infusion of the competitive HDAC inhibitor suberanilohydroxamic acid (SAHA) show a marked reduction in myocardial [¹¹**C**]Martinostat signal. (E) Time activity curves from the myocardium corresponding to the baseline and SAHA-blocked images. (F) The percent-difference in the myocardial SUVs produced by pre-injection increases with time and reaches a peak of 50%. The displacement of [¹¹C]Martinostat produced by SAHA reflects the specificity of [¹¹C]Martinostat for cardiac HDACs, but is limited by the dose of SAHA that can be safely given *in vivo*. Uptake of the probe in the liver is non-specific and is not blocked by SAHA.

References:

 Wang C, Schroeder FA, Wey HY, Borra R, Wagner FF, Reis S, Kim SW, Holson EB, Haggarty SJ and Hooker JM. In vivo imaging of histone deacetylases (HDACs) in the central nervous system and major peripheral organs. *J Med Chem*. 2014;57:7999-8009.